5 Stocks Gaining Ground on Thursday
In this article, we will discuss five stocks that are gaining ground on Thursday.
Eiger Biopharmaceuticals Inc. (EIGR)
Market is closed
News
- Displaying 10
Were Hedge Funds Right About Eiger BioPharmaceuticals, Inc. (EIGR)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Are Done Buying Eiger BioPharmaceuticals, Inc. (EIGR)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Did Hedge Funds Make The Right Call On Eiger BioPharmaceuticals, Inc. (EIGR) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Hedge Funds Can't Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge ...
Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second ...
Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database.
P.A.W. Capital Partners’ Returns, AUM, and Holdings
P.A.W. Capital Partners is a Greenwich-based hedge fund launched at the end of 1990 by its current Chief Investment Officer, General Partner and Senior Portfolio Manager, Peter A. Wright.
What To Look Out For In The Latest Eiger Biopharmaceuticals Inc (EIGR) Trial
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) just announced first dosing in its phase II LIBERTY trial, and markets seem to have turned a blind eye to the development.
Billionaire Hedge Funds
